Literature DB >> 26475012

Disparity in market prices for hepatitis C virus direct-acting drugs.

Isabelle Andrieux-Meyer1, Jennifer Cohn2, Evaldo S Affonso de Araújo3, Saeed S Hamid4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26475012     DOI： 10.1016/S2214-109X(15)00156-4

Source DB:  PubMed          Journal:  Lancet Glob Health        ISSN： 2214-109X            Impact factor:   26.763


× No keyword cloud information.
  29 in total

1.  Recommendations on hepatitis C screening for adults.

Authors:  Roland Grad; Brett Thombs; Marcello Tonelli; Maria Bacchus; Richard Birtwhistle; Scott Klarenbach; Harminder Singh; Veronique Dorais; Nathalie Holmes; Wendy Martin; Rachel Rodin; Alejandra Jaramillo Garcia
Journal:  CMAJ       Date:  2017-04-24       Impact factor: 8.262

Review 2.  The legal determinants of health: harnessing the power of law for global health and sustainable development.

Authors:  Lawrence O Gostin; John T Monahan; Jenny Kaldor; Mary DeBartolo; Eric A Friedman; Katie Gottschalk; Susan C Kim; Ala Alwan; Agnes Binagwaho; Gian Luca Burci; Luisa Cabal; Katherine DeLand; Timothy Grant Evans; Eric Goosby; Sara Hossain; Howard Koh; Gorik Ooms; Mirta Roses Periago; Rodrigo Uprimny; Alicia Ely Yamin
Journal:  Lancet       Date:  2019-04-30       Impact factor: 79.321

Review 3.  Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?

Authors:  Madhumita Premkumar; Gagandeep S Grover; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2017-09-23

Review 4.  The Elimination of Hepatitis C as a Public Health Threat.

Authors:  Margaret Hellard; Sophia E Schroeder; Alisa Pedrana; Joseph Doyle; Campbell Aitken
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

5.  Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario.

Authors:  Marina Morgado Garcia; Pamela Santos Azevedo; Andrew Mirelman; Leandro Pinheiro Safatle; Roberto Iunes; Marion Clark Bennie; Brian Godman; Augusto Afonso Guerra Junior
Journal:  Front Pharmacol       Date:  2020-04-14       Impact factor: 5.810

6.  Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.

Authors:  Guo-Feng Chen; Lai Wei; Jing Chen; Zhong-Ping Duan; Xiao-Guang Dou; Qing Xie; Wen-Hong Zhang; Lun-Gen Lu; Jian-Gao Fan; Jun Cheng; Gui-Qiang Wang; Hong Ren; Jiu-Ping Wang; Xing-Xiang Yang; Zhan-Sheng Jia; Qing-Chun Fu; Xiao-Jin Wang; Jia Shang; Yue-Xin Zhang; Ying Han; Ning Du; Qing Shao; Dong Ji; Fan Li; Bing Li; Jia-Liang Liu; Xiao-Xia Niu; Cheng Wang; Vanessa Wu; April Wong; Yu-Dong Wang; Jin-Lin Hou; Ji-Dong Jia; Hui Zhuang; George Lau
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

7.  Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.

Authors:  Swathi Iyengar; Kiu Tay-Teo; Sabine Vogler; Peter Beyer; Stefan Wiktor; Kees de Joncheere; Suzanne Hill
Journal:  PLoS Med       Date:  2016-05-31       Impact factor: 11.069

8.  Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C.

Authors:  Andrew Hill; Bryony Simmons; Dzintars Gotham; Joseph Fortunak
Journal:  J Virus Erad       Date:  2016-01-01

9.  Drug Pricing Evolution in Hepatitis C.

Authors:  Nathalie Vernaz; François Girardin; Nicolas Goossens; Urs Brügger; Marco Riguzzi; Arnaud Perrier; Francesco Negro
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

10.  The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?

Authors:  Jack Stone; Natasha K Martin; Matthew Hickman; Margaret Hellard; Nick Scott; Emma McBryde; Heidi Drummer; Peter Vickerman
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.